Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis Says Gilenya Showed Positive Clinical Outcomes In Phase III 2309 Study

RELATED NEWS
Trade NVS now with 

Novartis AG (NVS: Quote) announced new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis, or RRMS, treated with Gilenya, or fingolimod, had a statistically significant 48% reduction in annualized relapse rates at 24 months compared to placebo.

According to the company, study 2309 is the third Phase III clinical trial to demonstrate a significant reduction of relapse rates with Gilenya treatment in patients with RRMS.

Novartis noted that a reduction of brain volume loss, a pre-defined key secondary endpoint for study 2309, also achieved statistical significance for Gilenya-treated patients compared to placebo. Brain volume loss is valued as a predictor of long-term disability.

Moreover, safety and tolerability were broadly consistent with previous clinical trials.

"Study 2309 confirms the efficacy of Gilenya across several key measures, including reductions in annualized relapse rate and reductions in brain volume loss," said David Epstein, Head of the Pharmaceuticals Division at Novartis Pharma AG. "With more than 20,000 patient years of fingolimod exposure to date, Gilenya continues to demonstrate its value to patients and the MS community. We are looking forward to presenting the full data to the clinical community at a scientific congress next year."

Register
To receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After reporting a modest uptick in U.S. producer prices in the previous month, the Labor Department released a report on Tuesday showing that producer prices came in unchanged in the month of August. The Labor Department said its producer price index for final demand was unchanged in August after inching up by 0.1 percent in July. Following the lackluster performance seen during the previous session, stocks may move to the downside in early trading on Tuesday. The major index futures are currently pointing to a moderately lower open for the markets, with the Dow futures down by 33 points. Germany's investor confidence weakened to a level last seen in late 2012 amid concerns that the rising geopolitical tensions are hurting the European economy, data from the Centre for European Economic Research/ZEW showed Tuesday. The ZEW economic sentiment index fell to 6.9 in September from 8.6 in August. The index has been falling since last January and matched the score seen in December 2012.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.